Nuvectis ended the third quarter with $140 million in cash.
NXP-100 demonstrated an average hemoglobin increase of 5 grams per deciliter.
NXP-200 achieved a 40% response rate in high-grade glioma patients.
On its third-quarter 2026 financial results call, held on Nov. 4, 2026, Nuvectis (NASDAQ:NVCT) announced its transition to a late-stage clinical drug developer after acquiring licensing rights for two drug candidates. The additions expand the company's oncology and rare disease pipeline, and $140 million in cash funds operations into the second half of 2029.
Three things management said stand out.
Licensing two late-stage drug candidates from Haisco Pharmaceutical Group gives Nuvectis ex-China development rights, which covers markets outside of China, while $140 million in cash provides operational runway into the second half of 2029.
We have transformed Nuvectis into a late stage development company with the addition of 2 exciting drug candidates with best in class potential through our licensing agreement for ex China rights with our new partner, Haisco.
-- Ron Bentsur, Chairman and Chief Executive Officer
Lead candidate NXP-100 treats paroxysmal nocturnal hemoglobinuria, a rare blood disorder known as PNH, using once-daily oral dosing compared to twice-daily alternatives like FABALTA.
We see a potentially substantial advantage for NXP-100 in its once daily dosing compared to the twice per day for FABALTA.
-- Ron Bentsur, Chairman and Chief Executive Officer
Second candidate NXP-200 targets mutated solid tumors and demonstrated complete responses in patients with recurrent high-grade glioma, a brain tumor, including those with prior therapy exposure.
Updated phase 1b data from Haisco study in China demonstrated deep and durable single agent activity with NXP200, including complete responses in patients with recurrent or progressive gliomas.
-- Ron Bentsur, Chairman and Chief Executive Officer
Pipeline catalysts drive near-term milestones across clinical programs while capital reserves provide multiyear stability. Clinical efforts center on Food and Drug Administration, or FDA, regulatory pathways for PNH, investigational new drug, or IND, filings, and trial expansions in kidney and brain cancers.
With that runway, we have the financial strength to reach multiple value inflection points across our pipeline.
-- Ron Bentsur, Chairman and Chief Executive Officer
International partnerships and upcoming phase 1b updates in solid tumors position the business for key regulatory decisions in the United States and China.
We have several opportunities to deliver meaningful news in the near term, with the potential to create significant value across our pipeline.
-- Ron Bentsur, Chairman and Chief Executive Officer
Before you buy stock in Nuvectis Pharma, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nuvectis Pharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 22, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.